title: Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.
abstract: Glucocorticoid-induced osteoporosis (GIO) is the most frequent cause of secondary osteoporosis. GIO is linked to glucocorticoids (GC) daily assumption with maximum effect within first months of treatment and decreasing to basal levels as the therapy is discontinued. In Italy, primary prevention of GIO is suggested when GC therapy (prednisone >5 mg/day or equivalent) is taken for longer than 3 months. Lazio GISMO (Italian Group for Study and Diagnosis of Bone Metabolism Diseases) group organized the GC and Osteoporosis Epidemiology study (EGEO) to evaluate physician's approach in preventing GIO. The study involved 19 osteoporosis centers. Patients taking long-term GC therapy were recruited and information collected: medical history and anthropometric data, GC therapy, primary disease, physician's specialty, osteopororosis screening, and pharmacological intervention. The study included 1334 patients. Mean age was 63 ± 13 yr; 243 (18%) patients had a history of falls from standing position in the previous 12 months, 78 (35%) vertebral fractures, 91 (41%) fractures other than vertebral, 27 (12%) femoral fractures, and 27 (12%) multiple sites fractures. The molecules of GC more often prescribed were prednisone and 6-metil prednisolone. One thousand and forty patients (78%) were taking GC for more than 6 months. GC therapy was prescribed more frequently by rheumatologists (62%). Antiosteoporotic drugs for GIO prevention were prescribed in 431 patients (32%). Among the patients, only 27% (360) received calcium and vitamin D supplements, and 39% (319) treated by rheumatologists received anti-resorptive drugs. In conclusion, our data show that in Italy, as already described elsewhere, only a small subpopulation of GC-treated patients was supported by an anti-osteoporotic therapy, indicating the need to further stimulate awareness of both patients and specialists, prescribing GC therapy, to an appropriate and prompt GIO prevention.
authors.affiliation: Unità Operativa Semplice Reumatologia, Ospedale S. Pietro Fatebenefratelli, Rome, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Massafra
authors.forename: S
authors.initials: S
authors.lastname: Migliaccio
authors.forename: C
authors.initials: C
authors.lastname: Bancheri
authors.forename: F
authors.initials: F
authors.lastname: Chiacchiararelli
authors.forename: F
authors.initials: F
authors.lastname: Fantini
authors.forename: F
authors.initials: F
authors.lastname: Leoni
authors.forename: L S
authors.initials: LS
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Migliore
authors.forename: B
authors.initials: B
authors.lastname: Muccifora
authors.forename: C
authors.initials: C
authors.lastname: Napolitano
authors.forename: R
authors.initials: R
authors.lastname: Pastore
authors.forename: A
authors.initials: A
authors.lastname: Ragno
authors.forename: S
authors.initials: S
authors.lastname: Ronzoni
authors.forename: M
authors.initials: M
authors.lastname: Rotondi
authors.forename: M
authors.initials: M
authors.lastname: Tibaldi
authors.forename: P
authors.initials: P
authors.lastname: Villa
authors.forename: V
authors.initials: V
authors.lastname: Vinicola
authors.forename: E
authors.initials: E
authors.lastname: D'Erasmo
authors.forename: P
authors.initials: P
authors.lastname: Falaschi
authors.forename: G
authors.initials: G
authors.lastname: Minisola
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D015331:Cohort Studies; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D005938:Glucocorticoids